🧫
Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window
active
experiment
Created: 2026-04-26T06:56:03
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-de15783366ff
🧫 Experiment Protocol
In-VivoAlzheimer disease3xTg-AD mice with stratified p-tau217 status, IV exosome dosingproposed
Determine the optimal dosing window for p-tau217-triggered hUC-MSC exosome administration delivering lncRNA-0021, based on biomarker stratification, and evaluate neuroprotective efficacy in 3xTg-AD mice.
PRIMARY OUTCOME
Plasma p-tau217 biomarker levels and amyloid/tau pathology burden
EXPECTED OUTCOMES
P-tau217-stratified dosing reduces amyloid and tau pathology by >30% and improves cognitive performance (Y-maze, Barnes maze) vs. standard-dose exosome or vehicle controls.
SUCCESS CRITERIA
p-Tau217 plasma levels (ULSA), amyloid/tau IHC burden, cognitive behavioral scores; threshold: p < 0.05 vs. vehicle.
PROTOCOL
in-vivo
Source: auto-generated
🧫 Experiment Extras
ESTIMATED COST
$44,000
TIMELINE
11 months
MARKET PRICE
$0.50
STATUS
proposed
Scoring Dimensions
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.